Investing in Coherus BioSciences, Inc. (CHRS)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)12.34453
Intrinsic value (DCF)29.521224
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

Chirous Therapeutics, Inc. (CHRS) is a biopharmaceutical company that specializes in developing and commercializing novel treatments for rare diseases. The company was founded in 2005 and is headquartered in Needham, Massachusetts. CHRS utilizes its proprietary chemistry technology to discover and develop small molecule drugs for serious and life-threatening diseases. Their research focuses on improving the quality of life of patients with rare genetic disorders, such as Huntington's disease, spinal muscular atrophy, and cystic fibrosis. The company's portfolio includes multiple drug candidates in various stages of development, including some that have received orphan drug designation from the FDA. CHRS is committed to addressing unmet medical needs and providing hope and relief to patients and their families. They have a dedicated team of experienced scientists and researchers who work tirelessly to advance their cutting-edge therapies. With a strong focus on innovation and a compassionate approach towards patients, CHRS is poised to transform the treatment landscape for rare diseases and make a significant impact in the healthcare industry.